Skip to main content

Bergen Brunswig

(BBC) - Get Virtus LifeSci Biotech Clinical Trials ETF Report

missed Wall Street's expectations for the latest fourth quarter, but earnings and revenue rose from the year-ago period.

Excluding charges, the drug and medical products distributor earned $16 million, or 12 cents a share, compared with $11.6 million, or 9 cents a share, for the same period a year ago. Five analysts expected the company to earn 14 cents a share for the quarter, according to

First Call/Thomson Financial

Scroll to Continue

TheStreet Recommends


Revenue from continuing operations for the fourth quarter rose to $4.84 billion, up 15% from $4.22 billion last year, excluding bulk shipments.

The company also said it reached an agreement in principle to settle a derivative-security class-action lawsuit.

Shares of Bergen Brunswig were recently trading up 88 cents, or 8.5%, to $11.19 on the

New York Stock Exchange